Treatment-related data and outcome of 18 patients with SLVL and HCV infection
Course of SLVL with HCV therapy (n = 18) | |
| Mean follow-up, mo | 62.3 |
| Complete remission | 14 (78%) |
| Partial remission | 4 (22%) |
| Persistent positive B-cell clonality | 14 (100%) |
| Persistent positive MC | 18 (100%) |
| Interferon alone (n = 8) | |
| Complete response | 7 (87%) |
| Partial response | 1 (13%) |
| No response | 0 |
| Relapse | 1 (13%) |
| Interferon plus ribavirin (n = 10) | |
| Complete response | 7 (70%) |
| Partial response | 3 (30%) |
| No response | 0 |
| Relapse | 0 |
| Time to response, mo | |
| Negative HCV RNA | 3.9 ± 3.4 |
| Decrease spleen size | 4.2 ± 3.5 |
| Decrease villous lymphocytes count | 2.8 ± 2.7 |
| Side effects | 4 (22%) |
| Flulike symptoms | 2 |
| Encephalopathy | 1 |
| Thrombocytopenia | 1 |
| Dose reduction | |
| IFN-α | 2 (11%) |
| Ribavirin | 0 |
| Discontinuation | 0 |
| Death | 3 (17%) |
| Myocardial infarction | 1 |
| Hepatocellular carcinoma | 1 |
| Sepsis | 1 |
Course of SLVL with HCV therapy (n = 18) | |
| Mean follow-up, mo | 62.3 |
| Complete remission | 14 (78%) |
| Partial remission | 4 (22%) |
| Persistent positive B-cell clonality | 14 (100%) |
| Persistent positive MC | 18 (100%) |
| Interferon alone (n = 8) | |
| Complete response | 7 (87%) |
| Partial response | 1 (13%) |
| No response | 0 |
| Relapse | 1 (13%) |
| Interferon plus ribavirin (n = 10) | |
| Complete response | 7 (70%) |
| Partial response | 3 (30%) |
| No response | 0 |
| Relapse | 0 |
| Time to response, mo | |
| Negative HCV RNA | 3.9 ± 3.4 |
| Decrease spleen size | 4.2 ± 3.5 |
| Decrease villous lymphocytes count | 2.8 ± 2.7 |
| Side effects | 4 (22%) |
| Flulike symptoms | 2 |
| Encephalopathy | 1 |
| Thrombocytopenia | 1 |
| Dose reduction | |
| IFN-α | 2 (11%) |
| Ribavirin | 0 |
| Discontinuation | 0 |
| Death | 3 (17%) |
| Myocardial infarction | 1 |
| Hepatocellular carcinoma | 1 |
| Sepsis | 1 |